Literature DB >> 23466901

The extinguished BEACON of bardoxolone: not a Monday morning quarterback story.

John A Tayek, Kamyar Kalantar-Zadeh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23466901      PMCID： PMC3725304          DOI： 10.1159/000346950

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN： 0250-8095            Impact factor:   3.754


× No keyword cloud information.
  20 in total

1.  Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.

Authors:  Steven Van Laecke; Raymond Vanholder
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

2.  Fasting Ramadan in chronic kidney disease patients: clinical and biochemical effects.

Authors:  Bassam Bernieh; Mohammad Raafat Al Hakim; Yousef Boobes; Fikri M Abu Zidan
Journal:  Saudi J Kidney Dis Transpl       Date:  2010-09

3.  Novel equations to estimate lean body mass in maintenance hemodialysis patients.

Authors:  Nazanin Noori; Csaba P Kovesdy; Rachelle Bross; Martin Lee; Antigone Oreopoulos; Deborah Benner; Rajnish Mehrotra; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  Am J Kidney Dis       Date:  2011-01       Impact factor: 8.860

4.  The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis.

Authors:  Kamyar Kalantar-Zadeh; Elani Streja; Csaba P Kovesdy; Antigone Oreopoulos; Nazanin Noori; Jennie Jing; Allen R Nissenson; Mahesh Krishnan; Joel D Kopple; Rajnish Mehrotra; Stefan D Anker
Journal:  Mayo Clin Proc       Date:  2010-11       Impact factor: 7.616

5.  Mortality prediction by surrogates of body composition: an examination of the obesity paradox in hemodialysis patients using composite ranking score analysis.

Authors:  Kamyar Kalantar-Zadeh; Elani Streja; Miklos Z Molnar; Lilia R Lukowsky; Mahesh Krishnan; Csaba P Kovesdy; Sander Greenland
Journal:  Am J Epidemiol       Date:  2012-03-16       Impact factor: 4.897

6.  Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

Authors:  Glenn M Chertow; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Jürgen Floege; William G Goodman; Charles A Herzog; Yumi Kubo; Gerard M London; Kenneth W Mahaffey; T Christian H Mix; Sharon M Moe; Marie-Louise Trotman; David C Wheeler; Patrick S Parfrey
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

7.  Renal effects of prostaglandin A1 in patients with essential hypertension.

Authors:  S J Lee; J G Johnson; C J Smith; F E Hatch
Journal:  Kidney Int       Date:  1972-04       Impact factor: 10.612

8.  Urinary creatinine excretion rate and mortality in persons with coronary artery disease: the Heart and Soul Study.

Authors:  Joachim H Ix; Ian H de Boer; Christina L Wassel; Michael H Criqui; Michael G Shlipak; Mary A Whooley
Journal:  Circulation       Date:  2010-03-08       Impact factor: 29.690

9.  Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

Authors:  Pablo E Pergola; Philip Raskin; Robert D Toto; Colin J Meyer; J Warren Huff; Eric B Grossman; Melissa Krauth; Stacey Ruiz; Paul Audhya; Heidi Christ-Schmidt; Janet Wittes; David G Warnock
Journal:  N Engl J Med       Date:  2011-06-24       Impact factor: 91.245

10.  Bardoxolone methyl decreases megalin and activates nrf2 in the kidney.

Authors:  Scott A Reisman; Glenn M Chertow; Sudarshan Hebbar; Nosratola D Vaziri; Keith W Ward; Colin J Meyer
Journal:  J Am Soc Nephrol       Date:  2012-08-02       Impact factor: 10.121
View more
  15 in total

Review 1.  Drug development: how academia, industry and authorities interact.

Authors:  Silvio Garattini; Norberto Perico
Journal:  Nat Rev Nephrol       Date:  2014-08-05       Impact factor: 28.314

2.  N-acetyl-cysteine increases cellular dysfunction in progressive chronic kidney damage after acute kidney injury by dampening endogenous antioxidant responses.

Authors:  David M Small; Washington Y Sanchez; Sandrine F Roy; Christudas Morais; Heddwen L Brooks; Jeff S Coombes; David W Johnson; Glenda C Gobe
Journal:  Am J Physiol Renal Physiol       Date:  2018-01-10

Review 3.  The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases.

Authors:  Prashant Deshmukh; Sruthi Unni; Gopinatha Krishnappa; Balasundaram Padmanabhan
Journal:  Biophys Rev       Date:  2016-12-06

Review 4.  Diabetic nephropathy: diagnosis and treatment.

Authors:  Daniel Fineberg; Karin A M Jandeleit-Dahm; Mark E Cooper
Journal:  Nat Rev Endocrinol       Date:  2013-10-08       Impact factor: 43.330

Review 5.  The emerging role of the Nrf2-Keap1 signaling pathway in cancer.

Authors:  Melba C Jaramillo; Donna D Zhang
Journal:  Genes Dev       Date:  2013-10-15       Impact factor: 11.361

6.  Chemical tuning enhances both potency toward nrf2 and in vitro therapeutic index of triterpenoids.

Authors:  Ian M Copple; Luke M Shelton; Joanne Walsh; Denise V Kratschmar; Adam Lister; Alex Odermatt; Christopher E Goldring; Albena T Dinkova-Kostova; Tadashi Honda; B Kevin Park
Journal:  Toxicol Sci       Date:  2014-05-05       Impact factor: 4.849

7.  Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: biochemical, pharmacological and toxicological implications.

Authors:  Joanne Walsh; Rosalind E Jenkins; Michael Wong; Adedamola Olayanju; Helen Powell; Ian Copple; Paul M O'Neill; Christopher E P Goldring; Neil R Kitteringham; B Kevin Park
Journal:  J Proteomics       Date:  2014-05-21       Impact factor: 4.044

Review 8.  Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.

Authors:  Yan-Yang Wang; Yin-Xue Yang; Hong Zhe; Zhi-Xu He; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2014-10-23       Impact factor: 4.162

9.  Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.

Authors:  Ben C Creelan; Dmitry I Gabrilovich; Jhanelle E Gray; Charles C Williams; Tawee Tanvetyanon; Eric B Haura; Jeffrey S Weber; Geoffrey T Gibney; Joseph Markowitz; Joel W Proksch; Scott A Reisman; Mark D McKee; Melanie P Chin; Colin J Meyer; Scott J Antonia
Journal:  Onco Targets Ther       Date:  2017-08-29       Impact factor: 4.147

10.  Slowing progression of chronic kidney disease.

Authors:  Paul E Drawz; Mark E Rosenberg
Journal:  Kidney Int Suppl (2011)       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.